Heroin Addiction and Related Clinical Problems: 2026, 28: 1-4

Metrics and Clinical Responsibility in Addiction Medicine Publishing

Icro Maremmani

Heroin Addiction and Related Clinical Problems: 2026, 28: 5-14

Scientific evidence and clinical experience in the treatment of Alcohol Use Disorder: Disulfiram versus opioid agonist approaches

Albrecht Ulmer

Heroin Addiction and Related Clinical Problems: 2026, 28: 15-18

Psychological Counselling for Heroin Addicts in the Sri Lankan Context

Isuri De Silva, Nuwan Darshana, and Vijitha De Silva

Heroin Addiction and Related Clinical Problems: 2026, 28: 19-28

Compulsive Sexual Behaviour within Opioid Use Disorder: A Narrative Review of a Behavioural Marker of Addiction Severity

Usman Riaz, Gautam Shanmuga Dharmar Balasubramania Pandian, Rahul Bangar, and Pawan Angara

Heroin Addiction and Related Clinical Problems: 2026, 28: 29-36

Opioid Agonist Therapy with Levomethadone in Primary Dependence on Nitazenes – A Case Study

Uli Mühlan Muehlan, Fabian Pitter Steinmetz, Clemens Muehlan, Timur Liwinski, and Christoph Stoll

Heroin Addiction and Related Clinical Problems: 2026, 28: 37-48

Process evaluation of an Irish Remote Model of Opioid Agonist Treatment with a Focus on Rural Communities: An Embedded Mixed-Methods Study

Des Crowley, Claire Collins, Walter Cullen, Ide Delargy, Robyn Homeniuk, and Nandakumar Ravichandran

Heroin Addiction and Related Clinical Problems: 2026, 28: 49-58

Predictors of extended-release naltrexone adherence and relapse: Secondary outcomes from the MAT-PLUS pilot

Julia Thomas, Kevin Wenzel, Jennifer Carrano, Jennifer Stidham, and Marc Fishman

Heroin Addiction and Related Clinical Problems: 2026, 28: 59-68

Poor Empathy and High Impulsivity Characterize Individuals with Poor Daytime Sleepiness

Noya Ayali, and Einat Peles

Heroin Addiction and Related Clinical Problems: 2026, 28: 69-72

Continuation of COVID-19-Era Modifications to Opioid Agonist Treatment: Telemedicine, Reduced Supervision, and the Post-Pandemic Care Model

Des Crowley, and Marie Claire Van Hout

Heroin Addiction and Related Clinical Problems: 2026, 28: 73-84

Evaluation of patient outcome and satisfaction from Long-Acting Injectable Buprenorphine treatment in NHS Lanarkshire

Duncan R. B. Hill

Heroin Addiction and Related Clinical Problems: 2026, 28: 85-92

Addiction as a Chronic Illness. Treatment, Stabilisation and the Limits of Punitive Approaches in Substance Use Disorders within International Human Rights Frameworks

Icro Maremmani, Andrea Michelazzi, and Michele Capano

Heroin Addiction and Related Clinical Problems: 2026, 28: 93-102

Field survey with the users of mobile units for opioid agonist treatment in Slovenia

Andrej Kastelic

Heroin Addiction and Related Clinical Problems: 2026, 28: 103-110

The Hidden Phase of Regulated Relapse: A Case for Early Methadone Longterm Treatment in Opioid Use Disorder

Carlo Minestrini, and Icro Maremmani

Heroin Addiction and Related Clinical Problems: 2026, 28: 111-118

Impact and adaptation of social and medical care for people who use drugs during a period of system disruption (COVID-19): A Qualitative Study

Des Crowley, John Broughan, Nandakumar Ravichandran, Anita Whyte, and Walter Cullen

Heroin Addiction and Related Clinical Problems: 2026, 28: 119-130

Effectiveness of Extended-Release Buprenorphine in Custodial Settings and during the High-Risk Eight Weeks Post-Release: A Scoping Review

Nandakumar Ravichandran, Tishya Kumar, Marie Claire Van Hout, Walter Cullen, and Des Crowley

Heroin Addiction and Related Clinical Problems: 2026, 28: 131-138

Should off-label prescription of controlled medicines be notified?

Caroline Schmitt-Koopmann, Carole-Anne Baud, Stéphanie Beuriot, Barbara Broers, Cheryl Dickson, and Olivier Simon

Heroin Addiction and Related Clinical Problems: 2026, 28: 139-146

Heroin in Sri Lanka: Fifteen Years of Evolving Trends, Institutional Burden, and the Rise of Synthetic Drugs

Isuri De Silva, Nuwan Darshana, Nisangi Randima, Janithra De Silva, Badra Mallawaarachchi, Champa Wijesinghe, and Vijitha De Silva

Heroin Addiction and Related Clinical Problems: 2026, 28: 147-160

Attentional impulsivity as a mediator between nicotine dependence and addiction severity: evidence from individuals with methamphetamine use disorder

Yiming Ji, Yilian Zhao, Hengyu Li, Chuansheng Wang, Xian Li, Desheng Zhai, Lai Wei, Junqiang Zhao, Xiaojie Zhang, Mohd Afifuddin Bin Mohamad Mohamad, Mohammad Farris Iman Leong Bin Abdullah, Ruiling Zhang, and Bin Zhao

Heroin Addiction and Related Clinical Problems: 2026, 28: 161-170

The Fentanyl Analogue Outbreak in Sweden, 2016–2018: Lessons Learned

Bodil Monwell

Heroin Addiction and Related Clinical Problems: 2026, 28: 171-188

Smoking Harm Reduction in Opioid Use Disorder: From Neurobiology to Clinical Practice

Icro Maremmani, Peter Hajek, Angelo Giovanni Icro Maremmani, and Sharon Cox

Heroin Addiction and Related Clinical Problems: 2026, 28: 189-194

Opiate maintenance as a last-ditch pharmacological treatment for alcoholism? It makes sense but first consider a trial of well-supervised disulfiram

Colin Brewer